For the first time, there’s evidence a drug reduces risk of complications that are the top killer of diabetes patients: heart attacks, strokes and other cardiovascular damage. The makers of Jardiance – Eli Lilly and partner Boehringer Ingelheim – are releasing limited data from a 7,000-patient study indicating their year-old drug delayed the time until patients died of cardiovascular disease or suffered a heart attack or stroke.